Last Updated: July 11, 2026

Patent: 11,098,132

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,098,132

Title:	Anti-factor IX Padua antibodies
Abstract:	Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
Inventor(s):	Voelkel Dirk, Pachlinger Robert, Rottensteiner Hanspeter, Weber Alfred, Engelmaier Andrea
Assignee:	TAKEDA PHARMACEUTICAL COMPANY LIMITED
Application Number:	US16301962
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	United States Patent 11,098,132 Claims & Patent Landscape Analysis (US) US Patent 11,098,132 is an issued US patent, but the claim set is not provided in the input (“The claims are: …”). Without the actual claim text (or at least claim numbers with independent claims and key dependent claims), a complete, accurate analysis of claim scope, infringement-relevant elements, validity attack surfaces, and how the patent interacts with the US Orange Book and Paragraph IV/biosimilar risk is not possible. What is the claim scope of US Patent 11,098,132 and what does it cover? Answer: Cannot be determined from the provided information because the claims are not included. Which independent claims define the invention in US 11,098,132? Answer: Cannot be determined from the provided information because the claims are not included. Which dependent claims add narrower patentability hooks (formulations, methods, parameters)? Answer: Cannot be determined from the provided information because the claims are not included. What claim terms are likely to be construed narrowly or broadly (ingredients, ranges, steps, catalysts, intermediates)? Answer: Cannot be determined from the provided information because the claims are not included. How strong is the patent estate around US 11,098,132 (family breadth, priority, continuations)? Answer: Cannot be determined from the provided information because the claim set and the underlying bibliographic data (assignee, priority date, related continuations) are not included. What is the priority chain and how many continuation/divisional patents exist? Answer: Cannot be determined from the provided information. What jurisdictional reach exists beyond the US (PCT, EP, WO, CA, JP)? Answer: Cannot be determined from the provided information. How does US 11,098,132 map to specific technical “foreground” elements? Answer: Cannot be determined from the provided information. When does US 11,098,132 expire and what exclusivity risks remain? Answer: Cannot be determined because expiration depends on priority date, term adjustments (PTA), patent term adjustments, and possible terminal disclaimers, none of which are provided. What is the patent expiration date (not just the statutory 20-year date)? Answer: Cannot be determined from the provided information. Does PTA or PTE shift the effective enforcement window for US 11,098,132? Answer: Cannot be determined from the provided information. Are there terminal disclaimers that cap term beyond the apparent expiration? Answer: Cannot be determined from the provided information. What prior art is most likely to challenge US 11,098,132 under §102 and §103? Answer: Cannot be determined from the provided information because the claim subject matter is not included. What earlier publications anticipate key features in the independent claim? Answer: Cannot be determined from the provided information. What combination references are most likely to be used for obviousness? Answer: Cannot be determined from the provided information. What prosecution history signals vulnerability (amendments, examiner rejections, narrowing)? Answer: Cannot be determined from the provided information. Can US 11,098,132 be attacked via IPR or covered business method type grounds? Answer: Cannot be determined from the provided information because the claims are not included, and because the likelihood of IPR depends on filing date, claim types, and whether the claims are directed to statutory subject matter. What is the likely PTAB posture for similar claim categories (composition, method, process, system)? Answer: Cannot be determined from the provided information. Are there §101 subject-matter risks based on claim framing? Answer: Cannot be determined from the provided information. How would claim construction impact the IPR viability? Answer: Cannot be determined from the provided information. What is the Orange Book status of the drug covered by US 11,098,132 and what does that imply for generic entry? Answer: Cannot be determined because the drug/active ingredient and Orange Book listing(s) are not provided. Which FDA NDA/BLA is linked to the patent (listing numbers, submission dates)? Answer: Cannot be determined from the provided information. Are the listings tied to use-code, drug substance, drug product, or method-of-use? Answer: Cannot be determined from the provided information. Which generic applicants have filed Paragraph IV certifications against the listed patent? Answer: Cannot be determined from the provided information. What patent litigation affects US 11,098,132 (infringement, IPR, settlements)? Answer: Cannot be determined because litigation records and the underlying asserted product/parties are not provided. Which companies have asserted or been sued under US 11,098,132? Answer: Cannot be determined from the provided information. What settlements or consent judgments constrain enforcement? Answer: Cannot be determined from the provided information. What do district court or PTAB decisions say about claim scope and validity? Answer: Cannot be determined from the provided information. How does US 11,098,132 compare to other patents in the same technical space (competing families)? Answer: Cannot be determined because the invention domain and claim elements are not included. What are the closest US competitors (earliest priority, overlapping claim elements)? Answer: Cannot be determined from the provided information. Which families share the same assignee and which are licensing targets? Answer: Cannot be determined from the provided information. What are the main design-around routes implied by the claim language? Answer: Cannot be determined from the provided information. What formulations, dosages, and manufacturing methods are protected by US 11,098,132? Answer: Cannot be determined because the claims are not included. Is the protection directed to drug substance, drug product, or both? Answer: Cannot be determined from the provided information. Are specific ranges or process steps required to infringe? Answer: Cannot be determined from the provided information. Do the claims cover solid forms (polymorphs, salts, hydrates) or process intermediates? Answer: Cannot be determined from the provided information. What generic entry risks exist for products that might practice the unprovided claims? Answer: Cannot be determined because the protected elements are not provided. What would a “non-infringing” generic design-around need to change? Answer: Cannot be determined from the provided information. Which certification triggers the risk (paragraph IV vs. section viii carve-outs)? Answer: Cannot be determined from the provided information. What is the likely litigation strategy if a generic challenges validity? Answer: Cannot be determined from the provided information. Key Takeaways No analysis can be produced because the claim set and related bibliographic and regulatory identifiers needed to map enforceable scope to prior art, Orange Book listings, expiration, and litigation are not included. FAQs What are the independent claims in US Patent 11,098,132? Not provided in the input. What product or active ingredient is protected by US 11,098,132? Not provided in the input. When does US 11,098,132 expire in the US including PTA/terminal disclaimer effects? Not provided in the input. Has US 11,098,132 been asserted in district court or PTAB proceedings? Not provided in the input. Is US 11,098,132 listed in the Orange Book and how does that affect generic filing strategy? Not provided in the input. References (APA) No cited sources can be generated because no bibliographic, claim, assignee, drug identity, Orange Book, or litigation data were provided. More… ↓ ⤷ Start Trial

Details for Patent 11,098,132

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h.	OCTAPLAS	pooled plasma (human), solvent/detergent treated	For Injection	125416	January 17, 2013	11,098,132	2037-05-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.